The use of blister packs in the US pharmaceutical market continues to expand, but for the supporters of this type of packaging, the new study from The Freedonia Group, "The US Drug Packaging Market," is encouraging 12 edition.
Published in June 2017, Freedonia forecasts demand for pharmaceutical blister packaging will expand 6.5% per year, topping $4.4 billion in 2021, which it says represents 12.9 billion units.
Single-dose packaging of solid oral prescription drugs will continue to account for the largest usage of this pack style, says Freedonia, “whether dispensed directly to patients, tested in clinical trials, distributed as physicians’ samples or administered in hospitals. Blister packs are also widely employed as high-visibility containers for over-the-counter (OTC) tablets, caplets, and capsules sold in quantities of 50 or fewer.”
Turning to the OTC drug packaging market, Freedonia acknowledged that the conversion of former prescription drugs to non-prescription drugs was an important driving force for blister packaging. For example, Freedonia noted that Xyzal (levocetirizine dihydrochloride) is an allergy treatment that was approved by the FDA for OTC sales in January 2017. The OTC version of the drug was sold in 35-piece blister packs.
Article from:
https://www.packworld.com/
